SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is attracting significant market attention as traders bet on a potential short squeeze amid high short interest and heavy institutional buying. The community remains focused on upcoming regulatory catalysts, global manufacturing expansion for its cell therapy platform, and the company's long-term potential to transform oncology treatment.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant volatility as investors weigh a strong growth narrative against persistent stock price pressure near annual lows, fueled by concerns over Alani Nu integration and competitive dynamics. The community is actively debating whether current levels represent an institutional accumulation phase ahead of upcoming earnings or reflect deeper structural headwinds in the energy drink sector.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending following the successful closure of a $600 million AAA-rated asset-backed securities transaction, which has bolstered investor confidence in its AI-driven credit underwriting model. The community is currently focused on the stock's potential for a recovery, emphasizing its move toward sustained profitability and the expansion of its institutional partner network despite broader macro-economic and geopolitical headwinds.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending due to a significant stock price surge following a strong earnings report that topped expectations for both revenue and customer growth. The community is actively discussing the stock's resilience in the software sector, potential long-term benefits from AI infrastructure demands, and the reliability of its observability platform despite broader concerns about software sector valuations.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is currently trending due to a massive disconnect between its strong fundamentals and recent stock price volatility, with investors debating whether the stock is a 'profit machine' or vulnerable to dilution from a shelf offering. The community is sharply divided, with bulls pointing to record-breaking margins and AI-driven growth, while some bears are signaling caution regarding potential SEC investigation risks and the broader software sector's recent underperformance.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending following a surge in trading volume and investor interest sparked by a report highlighting its role as a key supplier for AI infrastructure and optics. The community is actively debating the sustainability of this rally, with discussions centered on potential institutional positioning, the impact of heavy call option activity, and the company's long-term integration into advanced data center technologies.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a major leadership overhaul and the acquisition of Kezar Life Sciences. The market is actively debating whether these aggressive moves under new management signal an accelerated path toward a potential buyout or a strategic shift in long-term pipeline development.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility driven by ongoing debates over Elevidys clinical efficacy and concerns regarding Roche's decision to initiate a new global Phase 3 trial for the therapy. While the community remains deeply polarizedwith some investors highlighting undervaluation relative to the company's approved portfolio and others raising alarms over regulatory hurdles and potential cash burnsentiment is further pressured by aggressive analyst downgrades and persistent short interest.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is drawing heavy investor attention as the company aggressively pivots to value-focused menus, including new low-cost offerings and specialty drink expansions designed to combat rising operational costs and intense competition. Community sentiment is mixed, with some traders betting on a defensive rotation into the stock as a recession hedge, while others voice concerns regarding menu quality and the effectiveness of current leadership.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending after reporting that its ERNA-101 cell therapy achieved complete tumor clearance and long-term survival in ovarian cancer models, fueling community speculation about its potential as a severely undervalued biotech opportunity. Investors are actively debating the significance of the preclinical animal data and the company's recent reverse split, with some highlighting it as a high-reward clinical candidate while others caution against potential future dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Datadog Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Datadog (DDOG) will release Q1 earnings on May 7, with analysts expecting 51 cents per share. Stock fell 1.4% on Wed. Analyst ratings and targets available.read more...

NCR Atleos (NATL) Q1 Earnings and Revenues Miss Estimates

NCR Atleos (NATL) delivered earnings and revenue surprises of -34.67% and -0.03%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Is It Worth Investing in Datadog (DDOG) Based on Wall Street's Bullish Views?

According to the average brokerage recommendation (ABR), one should invest in Datadog (DDOG). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

DDOG Gears Up to Report Q1 Earnings: What's in Store for the Stock?

Datadog eyes Q1 results with strong AI-driven momentum and bookings, but margin pressure and customer concentration risks may shape near-term stock moves.

Jefferies Financial Group Issues Positive Forecast for Datadog (NASDAQ:DDOG) Stock Price

Jefferies Financial Group boosted their price target on Datadog from $160.00 to $170.00 and gave the stock a 'buy' rating in a research note on Tuesday...

Datadog (NASDAQ:DDOG) Earns Buy Rating from DA Davidson

DA Davidson reaffirmed a 'buy' rating and set a $225.00 target price on shares of Datadog in a report on Monday...

$100 Invested In Datadog 5 Years Ago Would Be Worth This Much Today

PFA Pension Forsikringsaktieselskab Invests $22.84 Million in Datadog, Inc. $DDOG

PFA Pension Forsikringsaktieselskab purchased a new stake in Datadog, Inc. (NASDAQ:DDOG - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 166,138 shares of the company's stock, valued at app...

Cornerstone Planning Group LLC Sells 7,741 Shares of Datadog, Inc. $DDOG

Cornerstone Planning Group LLC lowered its holdings in shares of Datadog, Inc. (NASDAQ:DDOG - Free Report) by 96.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 259 shares of the company's stock after s...

Infrastructure Stocks To Follow Now - May 3rd

Marvell Technology, Nokia, Vertiv, Coinbase Global, Quanta Services, Astera Labs, and Datadog are the seven Infrastructure stocks to watch today, according to MarketBeat's stock screener tool. Infrastructure stocks are shares of companies that build, own, or operate the physical systems and facilit...

$DDOG Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.15 up 114.29% YoY
• Reported revenue of $1.01B up 32.15% YoY
• Datadog projects Q2 2026 revenue between $1.07B and $1.08B, with full year 2026 revenue expected between $4.3B and $4.34B, reflecting continued growth.

Stocktwits

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.15 up 114.29% YoY
• Reported revenue of $1.01B up 32.15% YoY
• Datadog projects Q2 2026 revenue between $1.07B and $1.08B, with full year 2026 revenue expected between $4.3B and $4.34B, reflecting continued growth.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

https://files.quartr.com/streams/2026-05-07/553c549d-4743-428f-9e47-66626817a0d7/2/live_transcript.jsonl?ref=U3RvY2t0d2l0cw==

DDOG  Earnings Call

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Stocktwits Polls

Investors are celebrating a strong double-beat quarter with over 30% revenue growth and optimistic guidance, fueling positive sentiment.

Wall Street analysts emphasize the company's role as core infrastructure for the AI revolution, specifically regarding cloud observability and enterprise data demand.

Some market participants are expressing caution as emerging rivals like Clickhouse potentially challenge the firm's dominance in specific data observability spaces.

DDOG
Datadog Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Earnings Recap

Latest DDOG News

DDOGDatadog Inc